GlassScriptPhysician profile
Tyler Jon Beach
NPI 1861983348
$1,547.47
in general payments reported to CMS, 2019-2025
15 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.94 · 2020: $38.90 · 2021: $190 · 2022: $59.49 · 2023: $85.14 · 2024: $681 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.25 | 2024-2025 | |
| Novo Nordisk INC | $302.85 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $255.61 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.08 | 2021-2025 | Jardiance |
| Pfizer INC. | $110.42 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $58.95 | 2024-2025 | Varivax, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2021 | |
| Sumitomo Pharma America, INC. | $27.89 | 2025 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $24.51 | 2024 | Crysvita |
| Gilead Sciences, INC. | $24.22 | 2021 | |
| Exact Sciences Corporation | $19.84 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $19.51 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $19.23 | 2024 | Auvelity |
| Abbott Laboratories | $18.35 | 2024 | Proclaim |
| Aquestive Therapeutics, INC. | $18.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.